Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial

Panahi, Yunes; Ghanei, Mostafa; Bashiri, Sepideh; Hajihashemi, Ali; Sahebkar, Amirhossein

doi:10.1055/s-0034-1389986

Cited by 100 publications

(87 citation statements)

References 61 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, curcumin has been shown to enhance hepatic activity of acyl-CoA oxidase and blunt lipid peroxidation through increasing hepatic glutathione levels and glutathione reductase activities, while reducing the levels of hydroperoxide and lipoperoxide and thiobarbituric acid reactive species (Shapiro and Bruck, 2005;Zingg et al, 2013). Antioxidant and antiinflammatory properties of curcumin have also been the subject several clinical trials in different patient populations (Panahi et al, 2015b;Panahi et al, 2015c;Panahi et al, 2014c;Panahi et al, 2012b;Sahebkar, 2014a;Sahebkar et al, 2013), showing significant reductions in circulating concentrations of pro-inflammatory cytokines, C-reactive protein and lipid peroxidation products and enhancement of the circulating levels of enzymatic and non-enzymatic antioxidants. Recently, curcumin has been shown to up-regulate the expression and activity of hepatic antioxidant enzymes in aflatoxin B1-intoxicated rats and attenuate histopathological features of liver damage (El-Bahr, 2015).…”

Section: Discussionmentioning

confidence: 99%

Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial

et al. 2016

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a global health problem. Although many aspects of NAFLD pathogenesis have been understood, there is a paucity of effective treatments to be used as the second line when lifestyle modification is insufficient. Curcumin, a natural polyphenol from turmeric, has been shown to be effective against development of hepatic steatosis and its progression to steatohepatitis, yet these beneficial effects have not been explored in clinical practice. The aim of this study is to investigate the effects of curcumin on hepatic fat content as well as biochemical and anthropometric features of patients with NAFLD. In this randomized double-blind placebo-controlled trial, patients with ultrasonographic evidence of NAFLD were randomly assigned to receive an amorphous dispersion curcumin formulation (500 mg/day equivalent to 70-mg curcumin) or matched placebo for a period of 8 weeks. Liver fat content (assessed through ultrasonography), glycemic and lipid profile, transaminase levels, and anthropometric indices were evaluated at baseline and at the end of follow-up period. The clinical trial protocol was registered under the Iranian Registry of Clinical Trials ID: IRCT2014110511763N18. Compared with placebo, curcumin was associated with a significant reduction in liver fat content (78.9% improvement in the curcumin vs 27.5% improvement in the placebo group). There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group. Curcumin was safe and well tolerated during the course of trial. Findings of the present proof-of-concept trial suggested improvement of different features of NAFLD after a short-term supplementation with curcumin. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Another less potent class of anti-inflammatory agents are plant-derived curcuminoids (turmeric). Oral curcuminoids significantly decrease serum levels of inflammatory mediators and improve lung function in chronically affected survivors of SM inhalation (Panahi et al, 2015). Macrolide antibiotics including erythromycin, azithromycin, roxithromycin, clarithromycin have been shown to possess anti-inflammatory activity.…”

Section: Targeting Inflammatory Cells and Tnfαmentioning

confidence: 99%

Mustard vesicant-induced lung injury: Advances in therapy

Weinberger

Malaviya

Sunil

et al. 2016

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

Most mortality and morbidity following exposure to vesicants such as sulfur mustard is due to pulmonary toxicity. Acute injury is characterized by epithelial detachment and necrosis in the pharynx, trachea and bronchioles, while long-term consequences include fibrosis and in some instances, cancer. Current therapies to treat mustard poisoning are primarily palliative and do not target underlying pathophysiologic mechanisms. New knowledge about vesicant-induced pulmonary disease pathogenesis has led to the identification of potentially efficacious strategies to reduce injury by targeting inflammatory cells and mediators including reactive oxygen and nitrogen species, proteases and proinflammatory/cytotoxic cytokines. Therapeutics under investigation include corticosteroids, N-acetyl cysteine, which has both mucolytic and antioxidant properties, inducible nitric oxide synthase inhibitors, liposomes containing superoxide dismutase, catalase, and/or tocopherols, protease inhibitors, and cytokine antagonists such as anti-tumor necrosis factor (TNF)-α antibody and pentoxifylline. Antifibrotic and fibrinolytic treatments may also prove beneficial in ameliorating airway obstruction and lung remodeling. More speculative approaches include inhibitors of transient receptor potential channels, which regulate pulmonary epithelial cell membrane permeability, non-coding RNAs and mesenchymal stem cells. As mustards represent high priority chemical threat agents, identification of effective therapeutics for mitigating toxicity is highly significant.

show abstract

“…alcoholic fatty liver disease [17,18], atherosclerosis [19,20], chronic complications due to sulfur mustard intoxication [21][22][23][24], solid tumors [25], colorectal cancer [26] and inflammation [27,28]. Several in vitro and animal studies have revealed the inhibitory effect of curcumin on H. pylori [29][30][31][32][33][34][35][36][37], however clinical studies evaluating the efficacy of curcumin supplementation in PU have been scarce.…”

Section: Introductionmentioning

confidence: 99%

Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial

Cited by 100 publications

References 61 publications

Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial

Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial

Mustard vesicant-induced lung injury: Advances in therapy

Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial

Contact Info

Product

Resources

About